MDGS logo

Xylo Technologies Ltd. (MDGS) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

MDGS, $ (piyasa değeri 0) fiyatla Healthcare işi olan Xylo Technologies Ltd.'i temsil ediyor. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 41/100 (ihtiyatlı) olarak derecelendirilmiştir.

Son analiz: 17 Mar 2026
41/100 AI Puanı

Xylo Technologies Ltd. (MDGS) Sağlık ve Boru Hattı Genel Bakışı

CEOLiron Carmel
Çalışanlar38
MerkezTel Aviv, IL
Halka Arz Yılı2015
SektörHealthcare

Xylo Technologies Ltd. is a diversified technology company focused on medical devices like the Medigus Ultrasonic Surgical Endostapler, alongside e-commerce and digital advertising platforms. Operating internationally, the company targets growth in healthcare and technology sectors, balancing innovation with diverse revenue streams and a $0.18B market cap.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 17 Mar 2026

Yatırım Tezi

Xylo Technologies Ltd. presents a multifaceted investment case centered on its diverse business segments and innovative product offerings. With a market capitalization of $0.18 billion and a P/E ratio of 1.83, the company shows potential for value creation. A key value driver is the Medigus Ultrasonic Surgical Endostapler (MUSE), targeting the GERD treatment market. Growth catalysts include expanding the market reach of MUSE and commercializing its biological gels. The company's involvement in e-commerce and digital advertising provides additional revenue streams. However, potential risks include competition in the medical device and technology sectors, the need for regulatory approvals, and the challenges of managing diverse business operations. The company's beta of 1.37 indicates higher volatility compared to the market.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Market capitalization of $0.18 billion indicates the company's current valuation in the market.
  • P/E ratio of 1.83 suggests the company may be undervalued compared to its earnings.
  • Profit margin of 20.3% demonstrates the company's ability to generate profit from its revenue.
  • Gross margin of 23.9% reflects the company's efficiency in managing production costs.
  • Beta of 1.37 indicates the stock is more volatile than the market average.

Rakipler & Benzerleri

Güçlü Yönler

  • Innovative medical device technology (MUSE).
  • Diversified business segments.
  • Established presence in multiple geographic markets.
  • Experienced management team.

Zayıflıklar

  • Small market capitalization.
  • Limited financial resources.
  • Dependence on regulatory approvals.
  • Competition in multiple sectors.

Katalizörler

  • Ongoing: Expansion of the Medigus Ultrasonic Surgical Endostapler (MUSE) into new geographic markets.
  • Ongoing: Commercialization of biological gels for protection against biological threats and allergens.
  • Ongoing: Growth in e-commerce and online advertising segments.
  • Upcoming: Potential partnerships with healthcare providers and technology companies to expand market reach (timeline: 6-12 months).

Riskler

  • Potential: Competition from larger medical device companies with greater resources.
  • Potential: Changes in healthcare regulations affecting the approval and reimbursement of medical devices.
  • Potential: Economic downturn impacting consumer spending and demand for e-commerce products.
  • Ongoing: Currency fluctuations affecting the value of the ADR.
  • Ongoing: Dependence on regulatory approvals for new products and technologies.

Büyüme Fırsatları

  • Expansion of Medigus Ultrasonic Surgical Endostapler (MUSE) Market: Xylo Technologies has the opportunity to expand the market reach of its MUSE system for GERD treatment. The global GERD market is expected to grow, driven by increasing prevalence and demand for minimally invasive procedures. By targeting new geographic markets and developing partnerships with healthcare providers, Xylo Technologies can increase its market share and revenue from MUSE. This expansion requires strategic marketing and distribution efforts, as well as ongoing clinical studies to demonstrate the efficacy and safety of the device. Timeline: Ongoing.
  • Commercialization of Biological Gels: The development and commercialization of biological gels to protect against biological threats and allergens represent a significant growth opportunity. With increasing concerns about airborne viruses and allergens, there is a growing demand for protective solutions. Xylo Technologies can capitalize on this demand by obtaining regulatory approvals and launching its biological gels in key markets. This opportunity requires further research and development, as well as strategic partnerships with pharmaceutical companies and healthcare providers. Market size: Unknown. Timeline: 1-2 years.
  • Growth in E-commerce and Online Advertising Segments: Xylo Technologies' involvement in e-commerce and online advertising provides additional growth opportunities. The global e-commerce market is expanding rapidly, driven by increasing internet penetration and online shopping trends. By optimizing its online stores and digital advertising platforms, Xylo Technologies can increase its revenue and profitability in these segments. This growth requires ongoing investment in technology and marketing, as well as a focus on customer satisfaction and retention. Market size: Unknown. Timeline: Ongoing.
  • Development of Wireless Vehicle Battery Charging Technologies: Xylo Technologies' foray into wireless vehicle battery charging technologies presents a long-term growth opportunity. The electric vehicle (EV) market is growing rapidly, driven by environmental concerns and government incentives. Wireless charging technologies offer convenience and efficiency for EV owners. By developing and commercializing its wireless charging solutions, Xylo Technologies can tap into this growing market. This opportunity requires significant investment in research and development, as well as strategic partnerships with automotive manufacturers and infrastructure providers. Market size: Unknown. Timeline: 3-5 years.
  • Expansion into New Therapeutic Areas: Xylo Technologies can explore opportunities to expand its product portfolio into new therapeutic areas within the healthcare sector. By leveraging its technological expertise and research capabilities, the company can develop innovative solutions for unmet medical needs. This expansion requires careful market research and strategic partnerships with healthcare providers and research institutions. Potential areas of focus include minimally invasive surgical procedures, diagnostic tools, and personalized medicine. Market size: Varies by therapeutic area. Timeline: 2-3 years.

Fırsatlar

  • Expansion into new geographic markets.
  • Development of new medical device applications.
  • Growth in e-commerce and digital advertising segments.
  • Partnerships with healthcare providers and technology companies.

Tehditler

  • Competition from larger medical device companies.
  • Changes in healthcare regulations.
  • Economic downturn affecting consumer spending.
  • Technological obsolescence.

Rekabet Avantajları

  • Proprietary technology in the Medigus Ultrasonic Surgical Endostapler.
  • Diversified business segments providing multiple revenue streams.
  • Established presence in the medical device market.
  • Expertise in digital advertising and e-commerce.

MDGS Hakkında

Xylo Technologies Ltd., formerly known as Medigus Ltd., was founded in 1999 and is headquartered in Tel Aviv-Yafo, Israel. The company has evolved into a technology-based entity providing medical-related devices and products across the United States, Europe, Asia, and Israel. Its core offering includes the Medigus Ultrasonic Surgical Endostapler (MUSE), an endoscopy system designed for the treatment of gastroesophageal reflux disease (GERD). Beyond its medical device focus, Xylo Technologies operates through multiple segments, including Corporate, E-commerce, Online Advertising & Internet Traffic Routing, Online Event Management, and Others. The company develops biological gels aimed at protecting patients from biological threats by reducing the intrusion of allergens and viruses through the upper airways and eye cavities. Additionally, Xylo Technologies engages in digital advertising, operates online stores on platforms like Amazon, and provides an online event management and ticketing platform. The company is also involved in the development of wireless vehicle battery charging technologies and modular electronic vehicles, demonstrating a diversified approach to technology innovation. Xylo Technologies aims to leverage its technological expertise across various sectors to drive growth and market presence.

Ne Yaparlar

  • Develops and markets the Medigus Ultrasonic Surgical Endostapler (MUSE) for GERD treatment.
  • Creates biological gels to protect against biological threats and allergens.
  • Operates e-commerce stores on platforms like Amazon.
  • Provides digital advertising and internet traffic routing services.
  • Offers an online event management and ticketing platform.
  • Develops wireless vehicle battery charging technologies.
  • Designs modular electronic vehicles.

İş Modeli

  • Sales of medical devices, including the Medigus Ultrasonic Surgical Endostapler.
  • Revenue from e-commerce activities through online stores.
  • Income from digital advertising and internet traffic routing services.
  • Fees from online event management and ticketing platform.
  • Potential future revenue from wireless vehicle battery charging technologies and modular electronic vehicles.

Sektör Bağlamı

Xylo Technologies Ltd. operates in the competitive medical device and technology industry, characterized by rapid innovation and evolving market demands. The medical device sector is driven by technological advancements, aging populations, and increasing healthcare expenditure. The company's focus on GERD treatment with the MUSE system positions it within the endoscopy market. Additionally, its involvement in e-commerce and digital advertising places it in the broader technology landscape. Competitors include companies like APTO, GMDA, HILS, MNK, and NBRVF. The company's success depends on its ability to innovate, obtain regulatory approvals, and effectively market its products and services.

Kilit Müşteriler

  • Hospitals and medical centers using the Medigus Ultrasonic Surgical Endostapler.
  • Consumers purchasing products through the company's e-commerce stores.
  • Businesses utilizing the company's digital advertising and internet traffic routing services.
  • Event organizers and attendees using the online event management and ticketing platform.
  • Potential customers for wireless vehicle battery charging technologies and modular electronic vehicles.
AI Güveni: 71% Güncellendi: 17 Mar 2026

Finansallar

Grafik & Bilgi

Xylo Technologies Ltd. (MDGS) hisse senedi fiyatı: Price data unavailable

Son Haberler

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

MDGS için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

MDGS için Wall Street fiyat hedefi analizi.

MoonshotScore

41/100

Bu puan ne anlama geliyor?

MoonshotScore, MDGS'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

Yönetim: Liron Carmel

CEO

Liron Carmel serves as the CEO of Xylo Technologies Ltd., bringing leadership to a team of 38 employees. His background includes experience in managing technology-driven companies and driving innovation in the healthcare sector. Carmel's expertise spans strategic planning, business development, and operational management. He is focused on expanding Xylo Technologies' market presence and developing new products and services to meet evolving customer needs. His previous roles have equipped him with a strong understanding of the medical device and technology industries.

Sicil: Under Liron Carmel's leadership, Xylo Technologies has focused on diversifying its business segments and expanding its product offerings. Key achievements include the continued development and marketing of the Medigus Ultrasonic Surgical Endostapler (MUSE) and the exploration of new opportunities in e-commerce and digital advertising. Carmel has also overseen the company's efforts to develop wireless vehicle battery charging technologies and modular electronic vehicles.

Xylo Technologies Ltd. ADR Bilgileri Sponsorlu

An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. MDGS, as an ADR, allows U.S. investors to invest in Xylo Technologies Ltd., an Israeli company, without the complexities of cross-border transactions. Each MDGS ADR represents a specific number of Xylo Technologies Ltd. shares traded on its home market.

  • Ana Piyasa Sembolü: Tel Aviv Stock Exchange, Israel
  • ADR Seviyesi: 2
  • ADR Oranı: 1:1
Kur Riski: Investing in MDGS exposes U.S. investors to currency risk, as the value of the ADR can be affected by fluctuations in the exchange rate between the U.S. dollar and the Israeli Shekel. If the Shekel weakens against the dollar, the value of MDGS may decrease, even if the underlying stock price in Israel remains stable. Investors may want to evaluate this currency risk when evaluating the potential returns on MDGS.
Vergi Etkileri: U.S. investors in MDGS may be subject to foreign dividend withholding taxes imposed by the Israeli government. The standard withholding tax rate on dividends paid to foreign investors is typically around 25%, but this may be reduced by tax treaties between the U.S. and Israel. Investors should consult with a tax advisor to understand the specific tax implications of owning MDGS ADRs.
İşlem Saatleri: Trading hours for MDGS on the U.S. market align with standard U.S. stock market hours (9:30 AM to 4:00 PM EST). However, the Tel Aviv Stock Exchange (TASE) operates on different hours, typically from 9:30 AM to 4:30 PM Israel Standard Time (IST), which is 7 hours ahead of EST. This difference in trading hours may result in price discrepancies between the two markets, particularly during periods when one market is open and the other is closed.

Yatırımcılar Xylo Technologies Ltd. (MDGS) Hakkında Ne Soruyor

MDGS için değerlendirilmesi gereken temel faktörler nelerdir?

Xylo Technologies Ltd. (MDGS) şu anda yapay zeka skoru 41/100, düşük puanı gösteriyor. Temel güçlü yan: Innovative medical device technology (MUSE).. İzlenmesi gereken birincil risk: Potential: Competition from larger medical device companies with greater resources.. Bu bir finansal tavsiye değildir.

MDGS MoonshotScore'u nedir?

MDGS şu anda MoonshotScore'da 41/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

MDGS verileri ne sıklıkla güncellenir?

MDGS fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler MDGS hakkında ne diyor?

MDGS için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

MDGS'a yatırım yapmanın riskleri nelerdir?

MDGS için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Competition from larger medical device companies with greater resources.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

MDGS'ın P/E oranı nedir?

MDGS için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için MDGS'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

MDGS aşırı değerli mi, yoksa düşük değerli mi?

Xylo Technologies Ltd. (MDGS)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

MDGS'ın temettü verimi nedir?

Xylo Technologies Ltd. (MDGS) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Information is based on available company data and may be subject to change.
  • AI analysis is pending and may provide additional insights.
Veri Kaynakları

Popüler Hisseler